Details of the SBP

General Information of Synthetic Binding Protein (SBP) (ID: SBP000001)
SBP Name
Monobody Pegdinetanib
Synonyms
Angiocept; BMS-844203; CT-322; CT 322; VEGFR-2 inhibitor peptide CT-322; PEGylated Adnectin CT-322
Molecular Weight 10.4 kDa
Design Method Traditional methods (Site-directed mutagenesis and/or Directed evolution)
Highest Status Phase II
Sequence Length 94
Protein Scaffold Information of This SBP
Scaffold ID PS047
Scaffold Info
[1] , [2] , [3]
Scaffold Name Monobody
Scaffold Class Non-Antibody
Fold Type Beta-Sheets + Loops
Binding Target(s) of This SBP (BTS)
BTS Name Details Mechanism Application Affinity Research Organization Ref
Vascular endothelial growth factor receptor 2
BTS Info
Inhibitor Pancreatic cancer [ICD-11: 2C10.Z]; Non-Hodgkin lymphoma [ICD-11: 2B33.5]; Macular degeneration [ICD-11: 9B78.3Z]; Glioblastoma [ICD-11: XH7F82]; Colorectal cancer [ICD-11: 2B91.Z]; Non-small cell lung cancer [ICD-11: 2C25.Y] Kd: 11 nM Bristol-Meyers Squibb; Adnexus [1] , [2] , [3]
Clinical Trial Information of This SBP
EUCTR2008-006561-89-FR Click to show the Detail
Indication Metastatic Colorectal Cancer
Phase Phase II
Title A Randomized, Double-Blind, Phase II Trial of CT-322 (BMS-844203) plus Irinotecan, 5-FU and Leucovorin (FOLFIRI) versus Bevacizumab plus FOLFIRI as Second-Line Treatment for Metastatic Colorectal Cancer
Status Not Recruiting
Sponsor Bristol Myers Squibb International Corporation
EUCTR2008-006561-89-IT Click to show the Detail
Indication Metastatic Colorectal Cancer
Phase Phase II
Title A Randomized, Double-Blind, Phase II Trial of CT-322 (BMS-844203) plus Irinotecan, 5-FU and Leucovorin (FOLFIRI) versus Bevacizumab plus FOLFIRI as Second-Line Treatment for Metastatic Colorectal Cancer.-ND
Status Not Recruiting
Sponsor Bristol Myers Squibb International Corporation
EUCTR2008-007768-41-GB Click to show the Detail
Indication Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology (NSCLC)
Phase Phase II
Title A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer with Non-Squamous Histology Revised Protocol Number 04, incorporating Amendment 05 + Pharmacogenetics Blood Sample Amendment Number 01-Site Specific (version 2.0, dated 07-Jan-09)
Status Not Recruiting
Sponsor .
EUCTR2008-007768-41-IT Click to show the Detail
Indication Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology (NSCLC)
Phase Phase II
Title A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer with Non-Squamous Histology. Revised Protocol Number 01, incorporating Amendment 02.-ND
Status Not Recruiting
Sponsor Bristol-Myers Squibb International Corporation
NCT00374179 Click to show the Detail
Indication Advanced Solid Tumor; Non-Hodgkin's Lymphoma (NHL)
Phase Phase I
Title A Phase I, Escalating Dose Study of?CT-322, a VEGFR-2 Antagonist, as Monotherapy in Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma
Status Completed
Sponsor Adnexus, A Bristol-Myers Squibb R&D Company
NCT00562419 Click to show the Detail
Indication Recurrent Glioblastoma Multiforme
Phase Phase II
Title Phase II, 2-Part, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of CT-322 Monotherapy and Combination Therapy With Irinotecan in Patients With Recurrent Glioblastoma Multiforme
Status Unknown
Sponsor Adnexus, A Bristol-Myers Squibb R&D Company
NCT00768911 Click to show the Detail
Indication Glioblastoma Multiforme
Phase Phase I
Title Phase I, Open Label, Multi-Center Study To Evaluate The Safety And Tolerability of?CT-322?Administered In Combination With Focal Brain Radiotherapy And Temozolomide To Subjects With Newly Diagnosed Glioblastoma Multiforme
Status Unknown
Sponsor Adnexus, A Bristol-Myers Squibb R&D Company
NCT00850577 Click to show the Detail
Indication Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology (NSCLC)
Phase Phase II
Title A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 Versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer With Non-Squamous Histology
Status Terminated
Sponsor Bristol-Myers Squibb
NCT00851045 Click to show the Detail
Indication Metastatic Colorectal Cancer
Phase Phase II
Title A Randomized, Double-Blind, Phase II Trial of?CT-322?(BMS-844203) Plus Irinotecan, 5-FU and Leucovorin (FOLFIRI) Versus Bevacizumab Plus FOLFIRI as Second-Line Treatment for Metastatic Colorectal Cancer
Status Completed
Sponsor Bristol-Myers Squibb
NCT01146171 Click to show the Detail
Indication Solid Tumor
Phase Phase I
Title A Phase I Multiple Ascending Dose Study of BMS-844203 (CT-322) Monotherapy in Japanese Patients With Solid Tumors
Status Withdrawn
Sponsor Bristol-Myers Squibb
References
1 In vitro-engineered non-antibody protein therapeutics. Protein Cell. 2018 Jan;9(1):3-14.
2 Recent advances in the development of novel protein scaffolds based therapeutics. Int J Biol Macromol. 2017 Sep;102:630-641.
3 KEGG DRUG Database. Pegdinetanib